Sanofi US News

"AFib Support Team" Offers Insights on Comprehensive Approach to Management of Serious Heart Condition

Fluzone® High-Dose (Influenza Virus Vaccine) strengthens immune response in the 65+ population, an age group that suffers disproportionately from influenza and its complications

-- Combination Strengthens sanofi-aventis' Strategy to Accelerate Growth Through Innovation, Geographic Expansion and External Growth

Novel vaccine approach tested against one of the most common causes of hospital-acquired infection in Europe and North America

- Atul Dhir, M.D., Ph.D. has been appointed new BiPar CEO to continue growing entrepreneurial and innovative culture -

Final data confirm immunogenicity, safety profile

The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated

- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -

The first clinical trial data from America’s youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated

Taking Control of Your Diabetes (TCOYD) Calls on Marketing Leaders and Creative Minds to "Start Taking Action Now for Diabetes"

Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years

Women may delay treatment or seek injectable procedures

Company has now committed to produce 75.3 million doses of vaccine for the U.S. government

"AF Stat(TM) Call to Action for Atrial Fibrillation" Report Cites Limited Understanding, Disconnected Dialogue and Uncoordinated Care as Key Barriers to Improved Outcomes

Influenza A (H1N1) 2009 Monovalent Vaccine licensure a key U.S. milestone in preparing for pandemic response this Fall

Approval Includes Use in Patients Two Years and Older with Seasonal Nasal Allergies Which Affect Forty Percent of Children in the U.S.

New York City Proclaims August 20, 2009 “Pertussis Awareness Day”

- Prophylaxis with Lovenox® (enoxaparin sodium injection) offered a cost reduction per discharge -

Company responds to FDA recommendation for influenza virus strain change supplement

Early shipment of vaccine to assist public health in immunization planning

Leading international experts conclude that these analyses present inconclusive and conflicting data

Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter - - U.S. commercial launch planned for the summer of 2009

The CDC Reinstates Booster Dose of Hib Vaccine

Christopher A. Viehbacher Reaffirmed Sanofi-aventis’ Commitment to Access to Health during the Pacific Health Summit in Seattle

A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar

Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R)

Company to take first steps toward large-scale production

Initial U.S. order for bulk vaccine valued at $190 million

Sanofi Pasteur committed to increasing its seasonal and pandemic influenza preparedness

Sanofi-aventis and its vaccines division Sanofi Pasteur pursue pandemic preparedness plan in response to WHO Phase 4 influenza pandemic alert

Singer, actress and mother teams up with the March of Dimes and sanofi pasteur to launch national whooping cough education campaign